OTCMKTS:NVZMYNOVOZYMES A/S/S Stock Price, Forecast & News

$56.29

+0.95 (+1.72 %)

(As of 06/5/2020 01:52 PM ET)

Add

Compare

Today's Range

$56.10

Now: $56.29▼

$56.82

50-Day Range

$45.43

MA: $50.06▼

$54.88

52-Week Range

$37.99

Now: $56.29▼

$56.82

Volume18,452 shs

Average Volume30,817 shs

Market Capitalization$16.72 billion

P/E Ratio34.37

Dividend Yield0.94%

Beta0.74

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for NOVOZYMES A/S/S.

1.8 Community Rank

Outperform Votes
NOVOZYMES A/S/S has received 137 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NOVOZYMES A/S/S has received 243 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NOVOZYMES A/S/S has received 63.95% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote “Outperform” if you believe NVZMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
NOVOZYMES A/S/S is a leading dividend payer. It pays a dividend yield of 0.94%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
NOVOZYMES A/S/S does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, NOVOZYMES A/S/S will have a dividend payout ratio of 30.41 % next year. This indicates that NOVOZYMES A/S/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NOVOZYMES A/S/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.13% of the stock of NOVOZYMES A/S/S is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for NOVOZYMES A/S/S are expected to grow by 4.91% in the coming year, from $1.63 to $1.71 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NOVOZYMES A/S/S is 34.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.38.
Price to Earnings Ratio vs. Sector
The P/E ratio of NOVOZYMES A/S/S is 34.37, which means that it is trading at a more expensive P/E ratio than the Basic Materials sector average P/E ratio of about 22.49.
Price to Earnings Growth Ratio
NOVOZYMES A/S/S has a PEG Ratio of 24.86. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
NOVOZYMES A/S/S has a P/B Ratio of 9.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.99 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorBasic Materials

Current SymbolOTCMKTS:NVZMY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.novozymes.com

Phone45-4446-0000

Debt

Debt-to-Equity Ratio0.23

Current Ratio1.29

Quick Ratio0.76

Price-To-Earnings

Trailing P/E Ratio34.37

Forward P/E Ratio34.53

P/E Growth24.86

Sales & Book Value

Annual Sales$2.28 billion

Price / Sales7.33

Cash Flow$1.75 per share

Price / Cash Flow32.15

Book Value$6.10 per share

Price / Book9.23

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$511 million

Net Margins21.08%

Return on Equity26.90%

Return on Assets14.94%

Miscellaneous

Employees6,427

Outstanding Shares297,000,000

Market Cap$16.72 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions

How has NOVOZYMES A/S/S's stock been impacted by COVID-19 (Coronavirus)?

NOVOZYMES A/S/S's stock was trading at $45.0314 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVZMY stock has increased by 25.0% and is now trading at $56.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NOVOZYMES A/S/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for NOVOZYMES A/S/S.

When is NOVOZYMES A/S/S's next earnings date?

NOVOZYMES A/S/S is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for NOVOZYMES A/S/S.

How were NOVOZYMES A/S/S's earnings last quarter?

NOVOZYMES A/S/S (OTCMKTS:NVZMY) posted its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. NOVOZYMES A/S/S had a return on equity of 26.90% and a net margin of 21.08%. View NOVOZYMES A/S/S's earnings history.

How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S?

NOVOZYMES A/S/S announced an annual dividend on Friday, January 24th. Shareholders of record on Friday, February 28th will be given a dividend of $0.517 per share on Tuesday, March 17th. This represents a dividend yield of 1.01%. The ex-dividend date is Thursday, February 27th. This is a boost from NOVOZYMES A/S/S's previous annual dividend of $0.50. View NOVOZYMES A/S/S's dividend history.

Has NOVOZYMES A/S/S been receiving favorable news coverage?

Media stories about NVZMY stock have trended extremely negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NOVOZYMES A/S/S earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutNOVOZYMES A/S/S.

Who are some of NOVOZYMES A/S/S's key competitors?

Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Moderna (MRNA), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO) and Crispr Therapeutics (CRSP). View all competitors.

Who are NOVOZYMES A/S/S's key executives?

NOVOZYMES A/S/S's management team includes the following people:

Mr. Peder Holk Nielsen, Pres & CEO (Age 63)
Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)
Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)
Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)
Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46)

What is NOVOZYMES A/S/S's stock symbol?

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of NOVOZYMES A/S/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NOVOZYMES A/S/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $56.29.

How big of a company is NOVOZYMES A/S/S?

NOVOZYMES A/S/S has a market capitalization of $16.72 billion and generates $2.28 billion in revenue each year. NOVOZYMES A/S/S employs 6,427 workers across the globe.

What is NOVOZYMES A/S/S's official website?

The official website for NOVOZYMES A/S/S is www.novozymes.com.

How can I contact NOVOZYMES A/S/S?

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff